Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München

  • WKN: 843002
  • ISIN: DE0008430026
  • Land: Germany

Nachricht vom 09.07.2021 | 09:06

DGAP-DD: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
09.07.2021 / 09:06
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title: Dr.
First name: Joachim
Last name(s): Wenning

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München

b) LEI
529900MUF4C20K50JS49 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE0008430026

b) Nature of the transaction
Acquisition

c) Price(s) and volume(s)
Price(s) Volume(s)
226.05 EUR 15145.35 EUR
226.10 EUR 69638.80 EUR
225.85 EUR 84693.75 EUR
225.65 EUR 80105.75 EUR

d) Aggregated information
Price Aggregated volume
225.8676 EUR 249583.6500 EUR

e) Date of the transaction
2021-07-08; UTC+2

f) Place of the transaction
Name: Xetra
MIC: XETR



09.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021